Dora Dias-Santagata, Ph.D.
This page shows the publications co-authored by Dora Dias-Santagata and Justin Gainor.
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. Cancer Discov. 2016 10; 6(10):1118-1133.
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013 Aug 01; 19(15):4273-81.
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol. 2011 Dec; 22(12):2616-2624.
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. Cancer Discov. 2018 12; 8(12):1529-1539.
Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. JCO Precis Oncol. 2018; 2018.
Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy. Int J Radiat Oncol Biol Phys. 2017 May 01; 98(1):220.
Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping. J Thorac Oncol. 2016 08; 11(8):1242-1245.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.